When HHS Secretary Robert F. Kennedy Jr. abruptly terminated 22 federal mRNA vaccine contracts—worth a combined $500 million—the biotech sector was left reeling. This unprecedented move hits major players like Pfizer, Moderna, and Sanofi, marking one of the sharpest policy reversals in U.S. vaccine development history.
In this episode of the PharmaSource podcast, Ben Locwin unpacks the political, scientific, and economic ripple effects—and what it means for the nation’s pandemic preparedness going forward.